Literature DB >> 1512808

Prolonged toxicity with intermediate syndrome after combined parathion and methyl parathion poisoning.

J De Bleecker1, J Willems, K Van Den Neucker, J De Reuck, D Vogelaers.   

Abstract

A prolonged type of organophosphate toxicity, previously characterized as the Intermediate Syndrome, has been recognized in 6 out of 7 prospectively studied patients poisoned by insecticide containing parathion and methyl parathion in equal proportions. The clinical characteristics included respiratory paresis, weakness in the territories of several motor cranial nerves, neck flexors and proximal limb muscles, and depressed tendon reflexes, all lasting for several days or weeks. Electromyography in the early stages disclosed diverse types of impaired neuromuscular transmission. EMG normalization preceded clinical recovery. Severe plasma butyrylcholinesterase and erythrocyte acetylcholinesterase inhibition persisted along with the occurrence of Intermediate Syndrome-related symptoms. We conclude that combined parathion and methyl parathion poisoning is more likely to induce Intermediate Syndrome than parathion poisoning alone. The mechanisms underlying this difference remain obscure. The Intermediate Syndrome shows clinical and electromyographic hallmarks of combined postsynaptic impairment of neuromuscular transmission.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512808     DOI: 10.3109/15563659209021548

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  2 in total

1.  An intermediate syndrome after parathion poisoning.

Authors:  A C Senel; H Ulusoy; N Erciyes
Journal:  Intensive Care Med       Date:  2001-01       Impact factor: 17.440

2.  The spectrum of intermediate syndrome following acute organophosphate poisoning: a prospective cohort study from Sri Lanka.

Authors:  Pradeepa Jayawardane; Andrew H Dawson; Vajira Weerasinghe; Lakshman Karalliedde; Nicholas A Buckley; Nimal Senanayake
Journal:  PLoS Med       Date:  2008-07-15       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.